opioid growth factor
Pre-clinical- Indications
- Liver cancer, Intrahepatic bile duct cancer
Company intelligence / Profile preview
Primocure Pharma, Inc. is a private pharmaceutical company based in New York focused on developing small molecule therapeutics for oncology indications. Its lead asset, KAT‑101, targets fibrolamellar hepatocellular carcinoma and has reached Phase 2 clinical trials. The company previously received FDA orphan drug designation for an opioid growth factor–based therapy targeting liver and intrahepatic bile duct cancers but does not have any approved products yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Primocure Pharma, Inc..